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Abstract: The accumulation of aggregated forms of the -synuclein (SN) is associated with 
the pathogenesis of Parkinson’s disease (PD) and Dementia with Lewy Bodies. The loss of 
synapses is an important event in the pathogenesis of these diseases. Here we show that 
aggregated recombinant human SN, but not SN, triggered synapse damage in cultured 
neurons as measured by the loss of synaptic proteins. Pre-treatment with the selective 
cytoplasmic phospholipase A2 (cPLA2) inhibitors AACOCF3 and MAFP protected neurons 
against SN-induced synapse damage. Synapse damage was associated with the SN-induced 
activation of synaptic cPLA2 and the production of prostaglandin E2. The activation of cPLA2 
is the first step in the generation of platelet-activating factor (PAF) and PAF receptor 
antagonists (ginkgolide B or Hexa-PAF) also protect neurons against SN-induced synapse 
damage. SN-induced synapse damage was also reduced in neurons pre-treated with the 
cholesterol synthesis inhibitor (squalestatin). These results are consistent with the hypothesis 
that SN triggered synapse damage via hyperactivation of cPLA2. They also indicate that  
SN-induced activation of cPLA2 is influenced by the cholesterol content of membranes. 
Inhibitors of this pathway that can cross the blood brain barrier may protect against the 
synapse damage seen during PD. 
OPEN ACCESS
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1. Introduction 
Parkinson’s disease (PD) is a major neurodegenerative motor disorder which affects approximately 
2% of the population over 65. In addition to the defining characteristics of bradykinesia, resting tremor 
and rigidity, there significant psychiatric and autonomic symptoms are also observed in a large % of 
patients [1]. The most common of the non-motor symptoms is Parkinson’s disease dementia (PDD),  
with a cumulative prevalence up to 75% of cases [2]. Also observed in PD patients is Dementia with 
Lewy Bodies, a similar condition to PDD in which dementia, rather than motor symptoms, are the 
primary clinical manifestations. Dementia with Lewy Bodies is the second most common cause of dementia 
after Alzheimer’s disease and is characterized by progressive cognitive decline and parkinsonism [3]. 
Currently, treatment is based upon the alleviation of symptoms as there is no long-term cure for PD,  
PDD or Dementia with Lewy Bodies. 
The alpha-synuclein (SN) positive intraneuronal inclusion known as a Lewy body is a major 
histopathological feature of PD, PDD and Dementia with Lewy Bodies. While the presence of Lewy bodies 
in the substantia nigra is diagnostic for PD, aggregated SN is also seen in many non-nigral regions and 
consequently may account for the wide range of non-motor symptoms. The molecular mechanisms 
underlying the pathological changes in PD are poorly understood but aggregated forms of SN are thought 
to play a central role. SN is predominantly expressed in central nervous system neurons where it is 
found within pre-synaptic terminals where it regulates synaptic vesicle formation and neurotransmitter 
release [4,5] and can affect synaptic plasticity and hence learning [6]. Recent evidence suggests that 
aggregates of SN accumulate at the pre-synaptic membrane and trigger synapse damage in PD and 
Dementia with Lewy Bodies [7–9]. Furthermore, the transfer of SN aggregates to adjacent neurons [10,11] 
may account for the progression of SN pathology through the brain in a manner that is similar to the 
staging of tau pathology in Alzheimer’s disease [12]. Thus, synapse damage in the hippocampus is 
characteristic of the PD patients that develop dementia [13] and in a rat model of -synucleinopathy, 
synaptic damage preceded neuronal loss [14]. Thus, synapse damage is a common feature observed  
in PD, PDD and Dementia with Lewy Bodies. 
The molecular mechanisms that underlie SN aggregate-induced synapse damage are not understood. 
Such processes have been examined by incubating cultured neurons with SN aggregates [15] in a similar 
manner to how amyloid- (A) peptides are used to investigate the pathogenesis of Alzheimer’s disease. 
An understanding of the molecular mechanisms that underlie synapse damage caused by aggregated 
SN may help identify drugs that reduce this process. To investigate these mechanisms the effect of SN 
aggregates on cultured cortical neurons was studied; synaptic density was measured by quantifying the 
amounts of synaptophysin and cysteine string protein (CSP) using ELISAs [16]. The loss of synaptic proteins 
including synaptophysin shows a close correlation with cognitive decline in Alzheimer’s disease [17,18] 
and reflects the loss of other synaptic proteins from neuronal cultures [19]. In this study we used cultured 
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neurons to explore the role of specific cell signaling pathways and cholesterol in neuronal responses to 
aggregated SN. 
2. Results 
2.1. SN Triggered the Loss of Synaptic Proteins from Cultured Neurons 
The synapse damage seen in PD and Dementia with Lewy Bodies is closely associated with SN  
oligomers [7–9]. In an in vitro model the addition of aggregated recombinant human SN, but not SN, 
caused a dose-dependent reduction in synaptic proteins including synaptophysin [15] (Figure 1A) and 
CSP (Figure 1B) from cultured neurons. Immunoblots showed that the loss of synaptophysin and CSP 
from cultured neurons was accompanied by the loss of other synaptic proteins including synapsin-1 and 
vesicle-associated membrane protein (VAMP)-1 (Figure 1C). Incubation with SN did not affect the 
amounts of caveolin in neuronal cultures, nor did it significantly reduce cell viability as measured by  
the thiazolyl blue tetrazolium (MTT) method, indicating that there was no significant neuronal death  
in these cultures (98% cell viability ± 6 compared with 100% ± 5, n = 9, p = 0.43). 
 
Figure 1. -synuclein (SN) triggered the loss of synaptic proteins from neurons—The 
amounts of synaptophysin (A) and cysteine string protein (CSP) (B) in neurons incubated with 
SN () or SN () as shown. Values are means ± SD from triplicate experiments performed 
three times, n = 9; (C) Immunoblots showing the amounts of synapsin-1, vesicle-associated 
membrane protein (VAMP)-1 and caveolin in neurons incubated with control medium (1),  
1 μM SN (2), 1 μM SN (3); (D) Immunoblot showing aggregates of recombinant human SN 
separated by non-denaturing polyacrylamide gel electrophoresis (PAGE). 
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2.2. PLA2 Inhibitors Protect Neurons against SN-Induced Synapse Damage 
Prior studies showed that synapse damage induced by prion peptides or amyloid- (A), thought to be 
the causative agent in the pathogenesis of Alzheimer’s disease, was associated with activation of synaptic 
cytoplasmic phospholipase A2 (cPLA2) [16]. Here we show that SN, but not SN, caused a dose-dependent 
activation of cPLA2 in synaptosomes (Figure 2A). The activation of cPLA2 was accompanied by the 
release of prostaglandin (PG)E2 (Figure 2B). The synaptophysin content of neurons was not significantly 
affected by treatment with cPLA2 inhibitors, 5 μM arachidonyl trifluoromethyl ketone (AACOCF3) (100 units 
synaptophysin ± 4 compared to 101 ± 4, n = 12, p = 0.5) or 5 μM methyl arachidonyl fluorophosphonate 
(MAFP) (100 ± 4 vs. 102 ± 6, n = 12, p = 0.4) showing that these drugs did not stimulate synaptogenesis, 
nor did they damage synapses. In primary cultures pre-treatment with either 1 μM AACOCF3 or 1 μM 
MAFP protected neurons against the SN-induced reductions in synaptophysin (Figure 2C) and CSP 
(Figure 2D). In contrast, pre-treatment with phospholipase C inhibitors (10 μM U73122 or ethyl-18-OCH3) 
did not affect SN-induced reductions in synaptophysin and CSP. Collectively these results support  
the hypothesis that hyperactivation of cPLA2 is involved in involved in SN-induced synapse damage. 
2.3. Cyclooxygenase Inhibitors Protect Neurons against SN-Induced Synapse Damage 
Since PGE2 causes synapse degeneration [16] the effects of drugs that inhibit cyclo-oxygenases (COX), 
enzymes that convert arachidonic acid to prostaglandins, upon PGE2 production in synaptosomes was 
studied. Pre-treatment of synaptosomes with the COX inhibitors aspirin or ibuprofen significantly 
reduced the SN-induced increase in PGE2 (Figure 3A). In contrast pre-treatment with drugs that  
inhibit lipoxygenases (LOX), enzymes that convert arachidonic acid to leucotrienes, (caffeic acid or 
nordihydroguaiaretic acid (NDGA)) did not affect SN-induced increase in PGE2. Furthermore,  
pre-treatment of cultured neurons with aspirin or ibuprofen protected neurons against SN-induced loss 
of synaptophysin (Figure 3B) or CSP (Figure 3C) whereas pre-treatment with caffeic acid or NDGA  
had no significant effect. 
2.4. PAF Antagonists Protected against SN-Induced Synapse Degeneration 
The activation of PLA2 is also the first step in the production of platelet-activating factor (PAF) [20] 
that has been shown to cause synapse degeneration in vitro [21]. The addition of PAF receptor antagonists 
(1-O-Hexadecyl-2-acetyl-sn-glycerol-3-phospho-(N,N,N-trimethyl)-hexanolamine (Hexa-PAF), CV6209 
or ginkgolide B), in the range 0.1–10 μM, did not affect the amount of synaptophysin or CSP in cortical 
neurons. However, pre-treatment with 2 μM Hexa-PAF, 2 μM CV6209 or 1 μM ginkgolide B provided 
protection against SN-induced loss of synaptophysin (Figure 4A) or CSP (Figure 4B). Prior studies 
showed that PAF facilitates the production of prostaglandins [22] suggesting that one or more of the 
prostaglandins produced in response to SN are responsible for synapse degeneration. Here we show that 
pre-treatment of synaptosomes with PAF antagonists significantly reduced the SN-induced production 
of PGE2 by synaptosomes (Figure 4C). Prostaglandin E2, acts via specific prostanoid E receptors [23] 
and pre-treatment with the prostanoid E receptor antagonist AH13205, but not the prostanoid D receptor 
antagonist BWA868C, prevented the loss of synaptophysin and CSP in cortical neurons incubated with 
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SN (Figure 4D,E). Collectively, these results show that the effects of SN on synapses were ultimately 
mediated through prostanoid E receptors. 
 
Figure 2. PLA2 inhibitors protect neurons against SN-induced synapse damage—(A) The 
amounts of activated cPLA2 in synaptosomes incubated with SN () or SN () as shown. 
Values are means ± SD from triplicate experiments performed three times, n = 9; (B) The 
concentrations of PGE2 produced by synaptosomes incubated with control medium (), 500 nM 
SN () or 500 nM SN (striped bar). Values are means ± SD from triplicate experiments 
performed three times, n = 9. * = significantly higher than in control synaptosomes. The 
amounts of synaptophysin (C) and CSP (D) in neurons pre-treated with control medium (), 
phospholipase A2 inhibitors (1 μM AACOCF3 or 1 μM MAFP) () or phospholipase C 
inhibitors (10 μM U73122 or 10 μM ethyl-18-OCH3) (striped bars) and incubated with  
1 M SN. Values are means ± SD from triplicate experiments performed four times, n = 12. 
* = significantly higher than in control neurons incubated with SN. 
2.5. SN-Induced Activation of cPLA2 Is Cholesterol Sensitive 
The activation of cPLA2 is associated with its migration to specific membrane micro-domains by an 
N-terminal lipid binding motif [24]. Prior studies demonstrated that A-induced activation of cPLA2 in 
synaptosomes involved its translocation to lipid rafts [19]. Here we show that the addition of SN, but not 
SN, results in the migration of cPLA2 to detergent-resistant membranes (rafts) (Figure 5A). Rafts are 
dependent on cholesterol concentrations and the addition of 1 M SN, but not SN increased cholesterol 
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concentration in synaptosomes (Figure 5B) suggesting that the presence of SN triggered the formation 
of a raft in which cPLA2 was activated. To explore this hypothesis further the SN-induced activation of 
cPLA2 in synapses from cholesterol-depleted neurons was examined. Squalestatin is a cholesterol synthesis 
inhibitor [25] that reduced the cholesterol content of neurons [26]. Treating cultured neurons with 200 nM 
squalestatin reduced total cellular concentrations without affecting neuronal survival or synapse density 
in these cultures as measured by synaptophysin (99.2 units ± 3 compared with 100 ± 4, p = 0.67) or CSP 
(97.8 units ± 3.7 compared with 100 ± 4.1, p = 0.43). However the SN-induced activation of cPLA2 
was significantly reduced in synaptosomes from squalestatin-treated neurons when compared to control 
synaptosomes (Figure 5C) as was the SN-induced translocation of cPLA2 to rafts (Figure 5D). 
 
Figure 3. Cyclooxygenase inhibitors protect neurons against SN-induced synapse damage. 
(A) The concentrations of PGE2 produced by synaptosomes pre-treated with a vehicle 
control (), cyclooxygenase inhibitors (aspirin and ibuprofen) () or lipoxygenase inhibitors 
(caffeic acid and nordihydroguaiaretic acid (NDGA)) (striped bars) and incubated with 500 nM 
SN. Values are means ± SD from triplicate experiments performed three times, n = 9.  
* = significantly lower than control synaptosomes incubated with 500 nM SN. The amounts 
of synaptophysin (B) and CSP (C) in neurons pre-treated with a vehicle control (), 
cyclooxygenase inhibitors (aspirin and ibuprofen) () or lipoxygenase inhibitors (caffeic acid 
and NDGA) (striped bars) and incubated with 1 M SN. Values are means ± SD from 
triplicate experiments performed four times, n = 12. * = significantly higher than in control 
neurons incubated with SN. 
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Figure 4. Platelet-activating factor (PAF) antagonists protect neurons against SN-induced 
synapse damage—The amounts of synaptophysin (A) and CSP (B) in neurons pre-treated 
with a vehicle control () or PAF antagonists (1 μM H-PAF, ginkgolide B or CV6209 ()) 
and incubated with SN. *= significantly higher than in control neurons incubated with SN. 
Values are means ± SD from triplicate experiments performed four times, n = 12; (C) The 
concentrations of PGE2 produced by synaptosomes pre-treated with incubated with a vehicle 
control () or PAF antagonists (1 μM H-PAF, ginkgolide B or CV6209 ()) and incubated 
with 500 nM SN. Values are means ± SD from triplicate experiments performed three 
times, n = 9. * = significantly lower than control synaptosomes incubated with 500 nM SN. 
The amounts of synaptophysin (D) and CSP (E) in neurons pre-treated with a vehicle control (), 
the prostanoid EP receptor antagonist AH13205 () or the prostanoid DP receptor antagonist 
BWA868C (striped bars) and incubated with 1 M SN. Values are means ± SD from 
triplicate experiments performed four times, n = 12. * = significantly higher than in control 
neurons incubated with SN. 
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Figure 5. The SN-induced activation of synaptic cPLA2 is sensitive to cholesterol depletion. 
(A) The amounts of cPLA2 in rafts derived from synaptosomes incubated with control medium () 
1 M SN () or SN (striped bar). Values are means ± SD from triplicate experiments 
performed three times, n = 9; *=significantly higher than in control synaptosomes. (B) The 
concentrations of cholesterol in synaptosomes incubated with control medium () 1 M SN () 
or SN (striped bar). Values are means ± SD from triplicate experiments performed three 
times, n = 9. * = significantly higher than in control synaptosomes. The amounts of activated 
cPLA2 in synaptosomes pre-treated with control medium () or 1 M squalestatin () and 
incubated with 1 M SN or PLAP as shown. Values are means ± SD from triplicate 
experiments performed three times, n = 9; * = significantly lower than in control synaptosomes 
incubate with SN.(D) The amounts of cPLA2 in rafts derived from synaptosomes from 
neurons treated with control medium () or 1 M squalestatin () and incubated with 1 M 
SN. Values are means ± SD from triplicate experiments performed three times, n = 9.  
* = significantly lower than in control synaptosomes incubated with SN. 
2.6. The SN-Induced Synapse Damage Is Cholesterol Sensitive 
The role of cholesterol in SN-mediated synapse damage was examined. Pre-treatment with  
200 nM squalestatin protected neurons against the SN-induced loss of synaptophysin (Figure 6A) or 
CSP (Figure 6B). The efficacy of squalestatin was also tested; pre-treatment with squalestatin produced a 
dose-dependent increase in the synaptophysin content of neurons subsequently incubated with 1 μM SN 
(Figure 6C). The effects of squalestatin on concentrations of cholesterol in neurons were also dose dependent; 
there were significant correlations between the concentrations of cholesterol and synaptophysin, Pearson’s 
coefficient = 	0.908, p < 0.01 (Figure 6D) following the addition of 1 M SN. 
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Figure 6. Squalestatin protects neurons against SN-induced synapse damage—The amounts 
of synaptophysin (A) and CSP (B) in neurons pre-treated with control medium () or 200 nM 
squalestatin () and incubated with SN as shown. Values are means ± SD from triplicate 
experiments performed three times, n = 9; (C) The amounts of synaptophysin in neurons  
pre-treated with control medium () or squalestatin as shown () and incubated with 1 M 
aggregated SN. Values are means ± SD from triplicate experiments performed three times,  
n = 9; (D) There was a significant inverse correlation between the concentrations of cholesterol 
in neurons treated with squalestatin (200 nM to 25 nM) and the amounts of synaptophysin in 
these neurons after incubation with 1M aggregated SN, Pearson’s coefficient = 	0.908,  
p < 0.01. 
3. Discussion 
The present study utilized a pharmacological approach to determine the molecular mechanisms involved 
in synapse damage induced by aggregated SN in cultured neurons. We demonstrate that aggregates of SN, 
but not -SN, caused extensive synapse damage, as evidenced by the loss of synaptophysin and CSP,  
in cultured neurons. Of particular interest were the observations that the concentrations of SN used in 
these assays did not reduce levels of caveolin from neuronal cultures and neuronal viability was not 
affected. We conclude that the in vitro assays may be analogous to the processes that occur in areas of 
the PD/LBD brains where synapse damage occurs without any significant neuronal death. 
The unregulated activation of PLA2 is thought to be pivotal to the pathogenesis of several 
neurodegenerative diseases [27,28]. Prior studies showed that cPLA2 was highly enriched in synaptosomes 
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and that synapse damage in response to “natural A” and prion-derived peptides was dependent upon 
the activation of cPLA2 [16]. Others have also shown that the activation of cPLA2 is a key element  
in neurodegeneration induced by A peptides [29,30], in experimental Parkinson’s disease [31] and 
Alzheimer’s disease [32]. Here we show that the addition of aggregated SN increased the activation of 
synaptic cPLA2 suggesting that SN-induced activation of cPLA2 resident within synapses was responsible 
for synapse damage. In addition, the SN-induced synapse damage was reduced by pre-treatment with 
the cPLA2 inhibitors. Collectively, these results indicate that the activation of an endogenous cPLA2 is  
a pivotal event in synapse damage mediated by SN aggregates. 
The activation of PLA2 leads to the formation of a number of bioactive factors including prostaglandins, 
leucotrienes, docosanoids and PAF [20,33]. The fact that PAF antagonists reduced the SN-induced synapse 
damage are consistent with reports that PAF causes synapse damage [16,34]. We also note that the PAF 
antagonist ginkgolide B is a component of the Ginkgo biloba extract that have neuroprotective effects 
in animal models of Parkinson’s disease [35,36]. Synapse damage induced by SN aggregates was also 
reduced in neuronal cultures pre-treated with ibuprofen or aspirin, drugs that inhibit cyclooxygenases.  
The cyclooxygenases convert arachidonic acid to prostaglandins, including PGE2. Although PGE2 
facilitates memory formation at the synapse PGE2 [37], it is thought to be a “goldilocks mediator” and high 
concentrations cause synapse degeneration [16]. In this study a prostanoid EP receptor antagonists reduced 
synapse damage in response to SN consistent with the idea that the persistent activation of cPLA2  
by SN results in high concentrations of PAF and PGE2 that cause synapse damage. 
Disturbances in membrane cholesterol are a common indication of neurodegenerative diseases including 
Parkinson’s disease [38]. An extensive review of the role of cholesterol in PD and cellular and models 
of PD by Dolga and colleagues [39] showed that at least one epidemiological study has demonstrated 
that high total cholesterol concentrations was associated with an increased risk of PD [40]. The role of 
cholesterol in disease progression is inferred from studies examining the effects of cholesterol synthesis 
inhibitors. Thus, in transgenic mice overexpressing SN, SN aggregation and neuronal degeneration were 
strongly diminished by treatment with a cholesterol synthesis inhibitor [41]. In humans, the use of statins 
showed a statistically significant inverse association with PD in some reports [42,43] while other studies 
have reported no such association [44,45]. The inconsistent results may reflect the variable ability of 
different statins to penetrate the blood brain barrier. In this study we used the squalene synthetase 
inhibitor squalestatin, which inhibits cholesterol synthesis without affecting non-sterol products [46] to 
show that SN aggregates induced the activation of cPLA2 and synapse damage, and that these were 
cholesterol dependent. The concentrations of cholesterol in cell membranes affects many different cell 
functions; it is critical for the formation of rafts [47] that act as membrane platforms to concentrate 
molecules for cell signalling [48] including cPLA2 [49,50]. These results are consistent with the hypothesis 
that cholesterol depletion disrupts the formation of the raft in which SN activates cPLA2. 
4. Experimental Section 
Primary Neuronal Cultures—Cortical neurons were prepared from the brains of mouse embryos  
(day 15.5). Neurons were plated at 2 × 105 cells/well in 48 well plates (coated with 5 g/mL poly-L-lysine) 
in Ham’s F12 medium containing 5% foetal calf serum for 2 h. Cultures were shaken (600 r.p.m for  
5 min) and non-adherent cells removed by 3 washes in PBS. Neurons were grown in neurobasal medium 
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(NBM) containing B27 components and nerve growth factor (5 nM) for 10 days. Immunohistochemistry 
showed that the cells were greater than 95% neurofilament positive. Fewer than 3% of cells stained for 
glial fibrillary acidic protein (astrocytes) or for F4/80 (microglial cells). Neurons were incubated with 
peptides for 24 h, washed 3 times with PBS and homogenised in a buffer containing 150 mM NaCl,  
10 mM Tris-HCl, pH 7.4, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.2% sodium 
dodecyl sulphate (SDS) and mixed protease inhibitors (4-(2-Aminoethyl) benzenesulfonyl fluoride 
hydrochloride (AEBSF), Aprotinin, Leupeptin, Bestain, Pepstatin A and E-46) (Sigma,Poole, UK) and a 
phosphatase inhibitor cocktail including PP1, PP2A, microcystin LR, cantharidin and p-bromotetramisole 
(Sigma) at 106 cells/mL. Nuclei and cell debris was removed by low speed centrifugation (300× g for 5 min). 
Western Blotting—Samples were mixed with Laemmli buffer containing -mercaptoethanol, heated 
to 95 °C for 5 min and proteins were separated by electrophoresis on 15% polyacrylamide gels (PAGE). 
Proteins were transferred onto a Hybond-P PVDF membrane by semi-dry blotting. Membranes were 
blocked using 10% milk powder; synapsin-1 was detected with goat polyclonal (Santa Cruz Biotech, 
London, UK), vesicle-associated membrane protein (VAMP)-1 with mAb 4H302 (Abcam, Cambridge, 
UK) and caveolin with rabbit polyclonal antibodies to caveolin Santa Cruz Biotech. Human recombinant 
SN was separated by PAGE under non-denaturing conditions and was detected by incubation with mAb 
211 raised against amino acids 121 to 125 of human SN (Santa Cruz Biotech). These were visualized 
using a combination of biotinylated anti-mouse/goat/rabbit IgG (Sigma), extravidin-peroxidase and 
enhanced chemiluminescence. 
Synaptosome Preparations—Synaptosomes were prepared on a discontinuous Percoll gradient [51]. 
Briefly, 106 cortical neurones were homogenized at 4 °C in 1 mL of SED solution (0.32 M sucrose, 50 mM 
Tris-HCl, 1 mM EDTA, and 1 mM dithiothreitol, pH 7.4 and mixed protease/phosphates inhibitors  
(as above)). The preparation was centrifuged at 1000× g for 10 min. The supernatant was transferred to 
a 4-step gradient of 3, 7, 15, and 23% Percoll in SED solution and centrifuged at 16,000× g for 30 min at 
4 °C. The synaptosomes was collected from the interface of the 15% and 23% Percoll steps, washed twice 
(16,000× g for 30 min at 4 °C) and suspended in extraction buffer (150 mM NaCl, 10 mM Tris-HCl,  
10 mM EDTA, 0.2% SDS and mixed protease/phosphatase inhibitors). 
Isolation of DRMs—These membranes were isolated by their insolubility in non-ionic detergents as 
described [52]. Briefly, samples were homogenised in an ice-cold buffer containing 1% Triton X-100, 
10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 10 mM EDTA and mixed protease inhibitors and nuclei and 
large fragments were removed by centrifugation (300× g for 5 min at 4 °C). The post nuclear supernatant 
was incubated on ice (4 °C) for 1 h and centrifuged (16,000× g for 30 min at 4 °C). The supernatant was 
reserved as the detergent soluble membrane (DSM) while the insoluble pellet was homogenised in an 
extraction buffer containing 10 mM Tris-HCL, pH 7.4, 150 mM NaCl, 10 mM EDTA, 0.5% Nonidet  
P-40, 0.5% sodium deoxycholate, 0.2% SDS and mixed protease inhibitors at 106 cells/mL, centrifuged 
(10 min at 16,000× g) and the soluble material was reserved as the DRM fraction. 
Synaptophysin ELISA—The amount of synaptophysin in neuronal extracts was measured by ELISA [16]. 
Briefly, the capture mAb was anti-synaptophysin MAB368 (Millipore). Samples were added for 1 h and 
bound synaptophysin was detected using rabbit polyclonal anti-synaptophysin (Abcam) followed by a 
biotinylated anti-rabbit IgG (Dako), extravidin-alkaline phosphatase and 1 mg/mL 4-nitrophenol phosphate. 
Absorbance was measured on a microplate reader at 405 nm and the synaptophysin content of samples 
was expressed as units where 100 units was defined as the amount of synaptophysin in untreated neurons. 
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CSP ELISA—Maxisorb immunoplates were coated with a monoclonal antibody (mAb) to CSP  
(sc-136468, Santa Cruz) and blocked with 5% milk powder. Samples were added and bound CSP was 
detected using rabbit polyclonal anti-CSP (sc-33154, Santa Cruz) followed by a biotinylated anti-rabbit IgG, 
extravidin-alkaline phosphatase and 1 mg/mL 4-nitrophenol phosphate solution. Absorbance was measured 
at 405 nm. Samples were expressed as “units CSP” where 100 units was the amount of CSP in  
106 control cells. 
cPLA2 ELISA—The amount of cPLA2 in extracts was measured by ELISA as described [53]. Maxisorb 
immunoplates were coated with 0.5 μg/mL of mouse mAb anti-cPLA2 (clone CH-7—Upstate) and blocked 
with 5% milk powder in PBS + 0.1% tween 20 (PBST). Samples were incubated for 1 h and the amount of 
bound cPLA2 was detected using a goat polyclonal anti-cPLA2 (Santa-Cruz Biotech) followed by 
biotinylated anti-goat IgG, extravidin-alkaline phosphatase and 1 mg/mL pNPP solution. Absorbance was 
measured at 405 nm and the amount of cPLA2 protein expressed in units, 100 units = amount of cPLA2 in 
control preparations. 
Activated cPLA2 ELISA—The activation of cPLA2 is accompanied by phosphorylation of the 505 
serine residue which creates a unique epitope and can be measured by ELISA [16]. To measure the amount 
of activated cPLA2, an ELISA using a mAb (anti-cPLA2, clone CH-7) combined with rabbit polyclonal 
anti-phospho-cPLA2 (Cell Signalling Technology) followed by biotinylated anti-rabbit IgG (Sigma), 
extravidin-alkaline phosphatase and 1mg/mL pNPP solution. Absorbance was measured on a microplate 
reader at 405 nm. Results were expressed as “units activated cPLA2” (100 units = amount of activated cPLA2 
in control preparations). The amounts of PGE2 in synaptosomes were determined using a competitive enzyme 
immunoassay kit (Amersham Biotech, Amersham, UK) according to the manufacturer's instructions. 
Cholesterol and Protein Content—Cellular cholesterol and protein content were determined in cell 
extracts. Protein concentrations were measured using a micro-BCA protein assay kit (Pierce, Paisley, 
UK). The amounts of cholesterol were measured using the Amplex Red cholesterol assay kit (Invitrogen, 
Paisley, UK), according to the manufacturer’s instructions. Briefly, free cholesterol is oxidised by 
cholesterol oxidase to yield hydrogen peroxide and ketones. The hydrogen peroxide reacts with  
10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red Reagent) to produce highly fluorescent resorufin, 
which is measured by excitation at 550nm and emission detection at 590 nm. 
Peptides—Recombinant human SN and SN were purchased from Sigma. Stock solutions of peptides 
were stored at 1 mM, thawed on the day of use, diluted in culture medium and sonicated before they were 
added to neurons. 
Drugs—Acetyl salicylic acid (aspirin), AH13205, AACOCF3, BWA868C, caffeic acid, CV6209, 
ginkgolide B, Hexa-PAF, -Methyl-4-(isobutyl)phenylacetic acid (ibuprofen), MAFP, NDGA, U73122 
were obtained from Sigma. U73122 and ethyl-18-OCH3 were obtained from Biomol. Squalestatin was 
a gift from GlaxoSmithKline. Stock solutions were dissolved in ethanol or di-methyl sulphoxide 
(DMSO) and diluted in medium to obtain final working concentrations. Vehicle controls consisted of 
equivalent dilutions of ethanol or DMSO in culture medium. 
Statistical Analysis—Differences between treatment groups were determined by Student’s, 2 sample, 
paired T-tests. For all statistical tests significance was set at the 1% level. 
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5. Conclusions 
We conclude that the addition of SN reduced the synaptophysin and CSP content of cultured neurons 
in a tissue culture model of synapse damage. The SN-induced synapse damage was associated with 
increased activation of cPLA2 within synapses. Drugs that protect the synapse provide a rational strategy 
to treat neurodegenerative diseases. Here we show that cholesterol synthesis inhibitors, cPLA2 inhibitors, 
COX inhibitors and PAF receptor antagonists all protect cultured neurons against SN-induced synapse 
damage. Such results suggest that aberrant activation of the cPLA2 pathway by SN leads to synapse 
damage and suggests that drugs targeting this pathway, and which are able to cross the blood–brain 
barrier, should be considered for further testing in animal models of PD. 
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